Glucocorticoid receptor polymorphisms and intraocular pressure response to intravitreal triamcinolone acetonide

Ophthalmic Genetics

Volumn 29, Issue 4, 2008, Pages 166-170

  Gerzenstein, Sabrina M ^a   Pletcher, Mathew T ^b   Cervino, Alessandra C L ^c   Tsinoremas, Nicholas F ^d   Young, Brandon ^e   Puliafito, Carmen A ^f   Fini, M Elizabeth ^f   Schwartz, Stephen G ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^e SCRIPPS RESEARCH INSTITUTE   (United States)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Glucocorticoid receptor; Polymorphisms; Steroid response; Triamcinolone acetonide

Indexed keywords

GLUCOCORTICOID RECEPTOR; TRIAMCINOLONE ACETONIDE; GLUCOCORTICOID;

AGED; ARTICLE; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HUMAN; INTRAOCULAR PRESSURE; INTRON; MAJOR CLINICAL STUDY; MALE; PHARMACOGENOMICS; PRIORITY JOURNAL; RETINA DISEASE; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; DRUG EFFECT; GENETICS; INJECTION; MASS SPECTROMETRY; PHARMACOGENETICS; PILOT STUDY; POLYMERASE CHAIN REACTION; VITREOUS BODY;

AGED; FEMALE; GENOTYPE; GLUCOCORTICOIDS; HAPLOTYPES; HUMANS; INJECTIONS; INTRAOCULAR PRESSURE; INTRONS; MALE; PHARMACOGENETICS; PILOT PROJECTS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, GLUCOCORTICOID; RETINAL DISEASES; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TRIAMCINOLONE ACETONIDE; VITREOUS BODY;

EID: 56149110814     PISSN: 13816810     EISSN: 17445094     Source Type: Journal    
DOI: 10.1080/13816810802320217     Document Type: Article

References (24)

1. Spaide RF, Sorenson J, Maranan L. Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. Ophthalmology. 2005;112:301-304.
2. Martidis A, Duker JS, Greenberg PB, et al. Intravitreal injection of triamcinolone acetonide for refractory diabetic macular edema. Ophthalmology. 2002;109:920-927.
3. Ip MS, Gottlieb JL, Kahana A, et al. Intravitreal triamcinolone for the treatment of macular edema associated with central retinal vein occlusion. Arch Ophthalmol. 2004;122:1131-1136.
4. Rhee DJ, Peck RE, Belmont J, et al. Intraocular pressure alterations following intravitreal triamcinolone acetonide. Br J Ophthalmol. 2006;90:999-1003.
5. Smithen LM, Ober MD, Maranan L, Spaide RF. Intravitreal triamcinolone acetonide and intraocular pressure. Am J Ophthalmol. 2004;138:740-743.
6. Quiram PA, Gonzales CR, Schwartz SD. Severe steroid-induced glaucoma following intravitreal injection of triamcinolone acetonide. Am J Ophthalmol. 2006;141:580-582.
7. Kaushik S, Gupta V, Gupta A, Dogra MR, Singh R. Intractable glaucoma following intravitreal triamcinolone in central retinal vein occlusion. Am J Ophthalmol. 2004;137:758-760.
8. Viola F, Morescalchi F, Staurenghi G. Argon laser trabeculoplasty for intractable glaucoma following intravitreal triamcinolone. Arch Ophthalmol. 2006;124:133-134.
9. Shukla D, Vidhya N, Prasad NM, et al. Evaluation of patient age as a risk factor for intraocular pressure elevation after intravitreal triamcinolone. Am J Ophthalmol. 2007;144:453-454.
10. Galor A, Margolis R, Brasil OM, et al. Adverse events after intravitreal triamcinolone in patients with and without uveitis. Ophthalmology 2007;114:1912-1918.
11. Palmberg PF, Mandell A, Wilensky JT, Podos SM, Becker B. The reproducibility of the intraocular pressure response to dexamethasone. Am J Ophthalmol. 1975;80:844-856.
12. Becker B. Intraocular pressure response to topical corticosteroids. Invest Ophthalmol. 1965;4:198-205.
13. Becker B, Shin DH, Palmberg PF, Waltman SR. HLA antigens and corticosteroid response. Science. 1976;194:1427-1428.
14. Weinreb RN, Bloom E, Baxter JD, et al. Detection of glucocorticoid receptors in cultured human trabecular cells. Invest Ophthalmol Vis Sci. 1981;21:403-407.
15. Tissing WJ, Meijerink JP, den Boer ML, et al. Genetic variations in the glucocorticoid receptor gene are not related to glucocorticoid resistance in childhood acute lymphoblastic leukemia. Clin Cancer Res. 2005;11:6050-6056.
16. van Rossum EF, Koper JW, Huizenga NA, et al. A polymorphism in the glucocorticoid receptor gene, which decreases sensitivity to glucocorticoids in vivo, is associated with low insulin and cholesterol levels. Diabetes. 2002;51:3128-3134.
17. Huizenga NA, Koper JW, de Lange P, et al. A polymorphism in the glucocorticoid receptor gene may be associated with an increased sensitivity to glucocorticoids in vivo. J Clin Endocrinol Metab. 1998;83:144-151.
18. van Rossum EF, Koper JW, van den Beld AW, et al. Identification of the BclI polymorphism in the glucocorticoid receptor gene: association with sensitivity to glucocorticoids in vivo and body mass index. Clin Endocrin (Oxf). 2003;59:585-592.
19. Koper JW, Stolk RP, de Lange P, et al. Lack of association between five polymorphisms in the human glucocorticoid receptor gene and glucocorticoid resistance. Hum Genet. 1997;99:663-668.
20. McLaren NC, Moroi SE. Clinical implications of pharmacogenomics for glaucoma therapeutics. Pharmacogenomics J. 2003;3:197-201.
21. Schwartz SG, Ayala-Haedo JA, Kishor KS, Fini ME. Pharmacogenomics of open angle glaucoma. Curr Pharmacogenomics Personalized Med. 2008;6:121-125.
22. 1-adrenergic receptor polymorphisms and clinical efficacy of betaxolol hydrochloride in normal volunteers. Ophthalmology. 2005;112:2131-2136.
23. 2α receptor gene and response to latanoprost. Ophthalmology. 2007;114:1039-1045.
24. Zhang X, Clark AF, Yorio T. Heath shock protein 90 is an essential molecular chaperone for nuclear transport of glucocorticoid receptor beta. Invest Ophthalmol Vis Sci. 2006;47:700-708.